In addition to changes in ET-1 levels, endothelial dysfunction at the onset of HTN has also been documented through the use of other circulating biomarkers, such as asymmetric dimethylarginine (ADMA), oxidized LDL, and endothelial microvesicles. The gene discussed is EDN1; the disease is hypertensive disorder.